Among the 124 gliomas, 35.5% (44/124) had a IDH1 mutation, of which 97.7% (43/44) was R132H, and 2.3% (1/44) was R132S; and 2.4% (3/124) had an IDH2 mutation, of which 2 cases had a mutation at site 172 (R172W, R172K), and 1 case had a mutation at site 174 (A174Y). Here, IDH1 is linked to central nervous system cancer.